SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
| Condition(s) | Prostate Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer. |
| Who can participate | Inclusion Criteria: * Age 18 or older * Informed consent for treatment and study participation completed * Pathologically proven diagnosis of prostate adenocarcinoma * ECOG Performance Status 0-2 * No prior history of pelvic radiotherapy, brachytherapy, cryosurgery, HIFU, TURP or radical prostatectomy Exclusion Criteria: * Presence of nodal or distant metastasis on staging MRI or CT Abdomen/Pelvis and Bone scan within 90 days of enrolment (CT/MRI/Bone Scan are only required if the clinical risk of metastatic disease is sufficient to warrant these scans) * Plan for adjuvant chemotherapy post-radiotherapy * Serious medical comorbidities or other contraindications to HDR brachytherapy * Presence of inflammatory bowel disease * Presence of connective tissue disorder seen as a contraindication |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | Dr. Gerard Morton |
| Locations | Toronto, Ontario, Canada |
| Start date | 2020-12-23 |
| NCT ID | NCT04861415 |
| Official listing | https://clinicaltrials.gov/study/NCT04861415 |